Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes fromFinra
Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
WVE-006 is the most advanced candidate for AATD designed to restore functional wild-type AAT protein and reduce Z-AAT protein aggregation with potential for disease modification in both lung and liver phenotypes IND-enabling activities for WVE-006 are underway and Wave expects to submit clinical trial applications for WVE-006 in 2023 Wave is also pioneering new therapeutic applications for RNA editing, including activating gene pathways and upregulating gene expression CAMBRIDGE, Mass., Sept. 28
CAMBRIDGE, Mass., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to participate in an analyst-led fireside chat at the Chardan’s 6th Annual Genetic Medicines Conference in New York City on Tuesday, October 4, 2022, at 3:15 p.m. ET. A live webcas
Wave Therapeutics (WVE) provides a positive update from its ongoing phase Ib/IIa study evaluating one of its lead candidates, WVE-003, for Huntington's disease. Stock up.
Wave Life Sciences Ltd (NASDAQ: WVE) announced an update to the ongoing Phase 1b/2a SELECT-HD trial of WVE-003 for Huntington's disease (HD). Eighteen (18) participants have been dosed in the SELECT-HD trial. Single doses of WVE-003 up to 90 mg appeared generally safe and well-tolerated. Among participants in the 30 and 60 mg WVE-003 cohorts, the mean reduction in CSF mHTT from baseline was 22% (median reduction of 30%) at 85 days following a single dose. Related: Ahead Of Upcoming Data On Three
Single doses of WVE-003 appear generally safe and well-tolerated CSF mutant huntingtin (mHTT) protein was reduced following single doses of 30 or 60 mg; mean mHTT reduction across both cohorts was 22% (median reduction 30%) from baseline 85 days post-single dose Wild-type huntingtin (wtHTT) protein levels through day 85 appear consistent with allele-selectivity Expanding single dose cohorts to optimize dose level with data expected in 1H 2023 Continued clinical validation of PRISM platform and P
Focus on WVE-006, a first-in-class RNA editing development candidate for AATD, and feature AATD expert presentationCAMBRIDGE, Mass., Sept. 16, 2022 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced it will hold an analyst and investor webcast on Wednesday, September 28, 2022. The event will highlight WVE-006, Wave’s A-to-I RNA base editing oligo
Market forces rained on the parade of Wave Life Sciences Ltd. ( NASDAQ:WVE ) shareholders today, when the analysts...
There was a great deal of life in Wave Life Sciences (NASDAQ: WVE) stock on Thursday. As of midafternoon trading, investors had bid the company's share price up by more than 25%, comparing very favorably to the marginal gain eked out by the S&P 500 index. Before market open, Wave published its second-quarter results.